Type: device
Status: Pivotal Trial
Developer: Know Labs
Know Labs Bio-RFID technology uses radio-frequency spectroscopy to measure blood glucose non-invasively through the skin. No needles, no implants, no consumable test strips. The wrist-worn Isaac device received FDA Breakthrough Device designation in 2024. Pivotal accuracy trials running through 2025-2026 targeting MARD < 15% for non-adjunctive use.
Patented Bio-RFID spectroscopy emits specific radio-frequency signals through tissue. Glucose molecules produce a unique spectral absorption signature. Machine learning algorithms trained on paired invasive glucose measurements extract glucose concentration from the RF signal in real-time.
Year: 2025-2026